Revvity ($RVTY) Stock Forecast: Down 5.2% Today

What is Revvity?

Revvity (RVTY) operates in the diagnostics and life sciences sectors, focusing on innovative healthcare solutions. The stock experienced a bearish movement following recent financial developments.

Why is Revvity going down?

RVTY stock is down 5.2% on Jul 30, 2025 18:50

• Revvity exceeded expectations for Q2 earnings and revenue, indicating growth in the Diagnostics business and a rebound in Life Sciences sales, possibly boosting investor confidence.
• The revision of FY25 EPS guidance due to challenges related to China DRG policy may have caused investor concerns and influenced the stock's bearish trend.
• Despite consistently surpassing earnings estimates previously, uncertainties surrounding policy changes in key markets like China might have overshadowed the company's positive financial performance, contributing to the stock's decline.

RVTY Price Chart

RVTY Technical Analysis

RVTY News

Revvity Slashes Outlook As China Policy Deals Diagnostics Blow - Revvity ( NYSE:RVTY )

Revvity Q2 EPS of $1.18 beat the $1.14 estimate; revenue rose to $720.28 million, topping $710.71 million consensus. FY25 EPS guidance trimmed to $4.85-$4.95 from $4.90-$5.00 due to China DRG policy headwinds. Missed the rally? Learn exactly where the next leaders are emerging here. Revvity Inc.

https://www.benzinga.com/markets/earnings/25/07/46665188/revvity-slashes-outlook-as-china-policy-deals-diagnostics-blow

RVTY Posts Q2 Earnings & Sales Beat, Raises '25 Sales View

Revvity's second-quarter results showcase strong growth in its Diagnostics business, along with recovery in Life Sciences segmental sales.

https://www.zacks.com/stock/news/2629039/rvty-posts-q2-earnings-sales-beat-raises-25-sales-view

Revvity ( RVTY ) Surpasses Q2 Earnings and Revenue Estimates

Revvity (RVTY) delivered earnings and revenue surprises of +3.51% and +1.27%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2628091/revvity-rvty-surpasses-q2-earnings-and-revenue-estimates

Why Revvity ( RVTY ) is Poised to Beat Earnings Estimates Again

Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

https://www.zacks.com/stock/news/2617996/why-revvity-rvty-is-poised-to-beat-earnings-estimates-again

Trending Today

crypto.com ($CRO) Crypto Forecast: Down 5.0% Today

Monero ($XMR) Crypto Forecast: Down 5.6% Today

Ethereum ($ETH) Crypto Forecast: Up 9.0% Today

Cardano ($ADA) Crypto Forecast: Up 9.1% Today

Vaulta (prev.EOS) ($A) Crypto Forecast: Up 5.1% Today

XRP ($XRP) Crypto Forecast: Up 5.3% Today

Sonic (prev. FTM) ($S) Crypto Forecast: Up 5.2% Today

Toncoin ($TON) Crypto Forecast: Up 5.1% Today

Dogecoin ($DOGE) Crypto Forecast: Up 5.6% Today

GMT ($GMT) Crypto Forecast: Up 5.8% Today

Revvity Price History

30.06.2025 - RVTY Stock was down 5.2%

• Revvity exceeded expectations for Q2 earnings and revenue, indicating growth in the Diagnostics business and a rebound in Life Sciences sales, possibly boosting investor confidence.
• The revision of FY25 EPS guidance due to challenges related to China DRG policy may have caused investor concerns and influenced the stock's bearish trend.
• Despite consistently surpassing earnings estimates previously, uncertainties surrounding policy changes in key markets like China might have overshadowed the company's positive financial performance, contributing to the stock's decline.

22.03.2025 - RVTY Stock was up 5.1%

• Regarding the current market movement of RVTY:
• Investors may be looking at potential growth opportunities and recent strategic partnerships rather than the projected decline in Q1 earnings.
• Speculation about a possible recovery in the following quarters could be sparking increased buying activity.
• Positive market sentiment and broader industry trends might be influencing the stock's upward movement despite the anticipated drop in earnings.
• Insider information or market rumors could potentially be contributing to the rise in stock price, disregarding the predicted earnings decrease.

14.10.2023 - RVTY Stock was up 5.0%

• The investigation by Pomerantz LLP might have caused some uncertainty among investors, but it did not have a significant impact on the stock's bullish movement.
• Other positive factors, such as strong financial performance or favorable market conditions, likely contributed to the bullish movement of RVTY.
• Investors may have been optimistic about the future prospects of Revvity, Inc., leading to increased buying interest and driving the stock price higher.
• It is important to monitor any developments related to the investigation by Pomerantz LLP to assess any potential impact on the stock in the future.

04.10.2024 - RVTY Stock was up 3.0%

• RVTY surpassed Q3 earnings and revenue estimates, showing strong financial performance.
• The positive earnings surprise hints at solid performance in the Diagnostics segment.
• Despite facing challenges in the Life Sciences segment, the overall performance exceeded expectations, prompting the stock's bullish movement.
• Investor confidence in the company's future likely increased following the Q3 results.

13.01.2024 - RVTY Stock was down 5.0%

• The recent introduction of Revvity's clinical data science platform may not have a direct connection to RVTY's decline in the market.
• Various other factors, including weak financial performance or unfavorable market sentiment, could have played a role in the stock's downward trend.
• It is crucial to take into account any other developments or occurrences that might have impacted RVTY's bearish movement.

03.10.2023 - RVTY Stock was up 5.3%

• Revvity's disappointing Q3 report and lowered forecast initially caused a plunge in the stock, but it managed to recover and have a bullish movement.
• The company's earnings and sales missed estimates, reflecting the impact of increased market uncertainty.
• Despite the negative news, some articles suggest that Revvity is an undervalued gem in the medical diagnostics and research industry.
• Other life science tool providers may have been affected by Revvity's performance, leading to a broader bearish sentiment in the industry.

23.06.2025 - RVTY Stock was up 7.1%

• Revvity (RVTY) is expected to beat earnings estimates for the second quarter, as analysts are optimistic about its key metrics and overall performance.
• The positive outlook and anticipation of a strong earnings report likely contributed to the bullish movement in Revvity's stock price today.
• Investors are showing confidence in Revvity's potential for growth and profitability, driving the stock higher in anticipation of positive news from the upcoming earnings release.

03.03.2025 - RVTY Stock was down 5.1%

• The recent approval of Revvity's Auto-Pure 2400 platform by the FDA for high-throughput latent TB testing is a positive development reflecting improved accuracy and efficiency in disease diagnosis and treatment.
• Nevertheless, the market displayed a bearish reaction, potentially due to investors opting to secure profits after anticipating the FDA's approval.
• Concerns regarding competition in healthcare technology or broader market circumstances impacting RVTY's stock price could also have influenced the bearish sentiment among investors.
• Although the FDA approval marked a significant achievement for Revvity, short-term market forces and investor outlook likely contributed to the decline in RVTY stock value today.

22.06.2025 - RVTY Stock was up 5.1%

• The bullish movement in RVTY's stock price could be attributed to the market's anticipation of a positive earnings report for the second quarter.
• Investors seem optimistic about RVTY's ability to surpass earnings estimates, leading to increased buying activity and driving the stock price higher.
• The positive outlook for RVTY reflects the market's confidence in the company's performance and growth prospects, positioning it as a favorable investment option in the tech sector.

11.06.2024 - RVTY Stock was up 6.2%

• Investors are displaying confidence in Revvity, Inc. prior to its earnings call, indicating high hopes for favorable financial outcomes.
• The upcoming executive conference call demonstrates a commitment to transparency and proactive communication with shareholders, likely enhancing investor trust.
• The upward movement in the stock price may be attributed to expectations of strong performance in the second quarter, potentially driven by effective business strategies or initiatives for revenue growth.

27.01.2025 - RVTY Stock was down 5.3%

• Options market activities indicate potential insider information or speculation impacting Revvity's performance, leading to heightened selling pressure.
• Concerns or uncertainties regarding Revvity's future plans or financial outcomes may be influencing investors to adopt a more careful stance.
• The stock's downturn could also stem from traders cashing in profits after benefiting from its earlier positive performance, resulting in a temporary decrease in value.

10.05.2025 - RVTY Stock was up 4.1%

• RVTY stock experienced a strong bullish movement today, outperforming market expectations.
• The positive market sentiment could be attributed to the company's recent product launches and strategic partnerships, driving investor confidence in its growth potential.
• Investors are optimistic about RVTY's future earnings prospects, leading to increased buying interest and pushing the stock price higher.
• The bullish trend indicates a favorable outlook for RVTY, with potential for further upside as market conditions remain supportive.